• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

PerkinElmer (NY:PKI)

N/A UNCHANGED
Last Price Updated: 7:00 PM EDT, May 15, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about PerkinElmer

< Previous 1 2 3 Next >
News headline image
Revvity Announces Financial Results for the First Quarter of 2023
May 11, 2023
From Revvity, Inc.
Via Business Wire
News headline image
Launching Revvity: A Scientific Solutions Company Powering Innovation from Discovery to Cure
May 09, 2023
From Revvity, Inc.
Via Business Wire
News headline image
PerkinElmer Board Declares Quarterly Dividend
April 25, 2023
From PerkinElmer, Inc.
Via Business Wire
News headline image
PerkinElmer to Hold Earnings Call on Thursday, May 11, 2023
April 12, 2023
From PerkinElmer Inc.
Via Business Wire
News headline image
PerkinElmer Completes Divestiture of its Applied, Food and Enterprise Services Businesses
March 13, 2023
From PerkinElmer, Inc.
Via Business Wire
News headline image
PerkinElmer to Present at KeyBanc Capital Markets Life Sciences & MedTech Investor Forum
March 09, 2023
From PerkinElmer Inc.
Via Business Wire
News headline image
PerkinElmer Launches EnVison Nexus Multimode Plate Reader to Drive Improved Research and Discovery Workflows
February 24, 2023
From PerkinElmer, Inc.
Via Business Wire
News headline image
PerkinElmer to Present at Upcoming Investor Conferences
February 22, 2023
From PerkinElmer, Inc.
Via Business Wire
News headline image
PerkinElmer Announces Financial Results for the Fourth Quarter and Full Year of 2022
February 14, 2023
From PerkinElmer, Inc.
Via Business Wire
News headline image
PerkinElmer Board Declares Quarterly Dividend
January 26, 2023
From PerkinElmer, Inc.
Via Business Wire
News headline image
PerkinElmer To Hold Earnings Call on Tuesday, February 14, 2023; Updates Fourth Quarter Outlook
January 09, 2023
From PerkinElmer Inc.
Via Business Wire
News headline image
PerkinElmer to Present at J.P. Morgan Healthcare Conference
December 19, 2022
From PerkinElmer Inc.
Via Business Wire
News headline image
PerkinElmer Helps Accelerate Gene Therapy Research with Industry-First Ready-to-Use Viral Vector Assays
November 21, 2022
From PerkinElmer, Inc.
Via Business Wire
News headline image
PerkinElmer Announces its EONIS SCID-SMA Kit is First to Receive Marketing Authorization by U.S. FDA for SMA Screening in Newborns
November 14, 2022
From PerkinElmer Inc.
Via Business Wire
News headline image
PerkinElmer to Present at 2022 Stifel Healthcare Conference
November 10, 2022
From PerkinElmer Inc.
Via Business Wire
News headline image
PerkinElmer Announces Financial Results for the Third Quarter of 2022
November 08, 2022
From PerkinElmer, Inc.
Via Business Wire
News headline image
PerkinElmer Bolsters Sustainability Commitments and Builds Off Recent Progress in New ESG Report
November 07, 2022
From PerkinElmer Inc.
Via Business Wire
News headline image
PerkinElmer Board Declares Quarterly Dividend
October 26, 2022
From PerkinElmer, Inc.
Via Business Wire
News headline image
PerkinElmer to Hold Earnings Call on Tuesday, November 8, 2022; Updates Third Quarter Outlook
October 17, 2022
From PerkinElmer, Inc.
Via Business Wire
News headline image
PerkinElmer Donation Helps Significantly Expand Capacity for Sickle Cell Disease Screening in Ghana
October 13, 2022
From PerkinElmer Inc.
Via Business Wire
News headline image
PerkinElmer Unveils Industry-first Cell Analysis Solution to Streamline Cell and Gene Therapy Research and Manufacturing
September 26, 2022
From PerkinElmer, Inc.
Via Business Wire
News headline image
PerkinElmer’s Oxford Immunotec Receives U.S. FDA Approval for T-Cell Select to Automate Clinically Superior Tuberculosis Detection
September 22, 2022
From PerkinElmer
Via Business Wire
News headline image
PerkinElmer to Present at Upcoming Investor Conferences
August 24, 2022
From PerkinElmer Inc.
Via Business Wire
News headline image
PerkinElmer Announces Finance Leadership Transition
August 17, 2022
From PerkinElmer, Inc.
Via Business Wire
News headline image
New Mountain Capital Announces Intent to Acquire PerkinElmer’s Applied, Food and Enterprise Services Businesses for up to $2.45 Billion
August 01, 2022
From New Mountain Capital
Via Business Wire
News headline image
PerkinElmer Announces Financial Results for the Second Quarter of 2022
August 01, 2022
From PerkinElmer, Inc.
Via Business Wire
News headline image
PerkinElmer Accelerates Transformation into High Growth, High Margin Life Sciences & Diagnostics Company
August 01, 2022
From PerkinElmer, Inc.
Via Business Wire
News headline image
PerkinElmer Board Declares Quarterly Dividend
July 22, 2022
From PerkinElmer, Inc.
Via Business Wire
News headline image
PerkinElmer Elects Dr. Michelle McMurry-Heath to its Board of Directors
July 22, 2022
From PerkinElmer, Inc.
Via Business Wire
News headline image
PerkinElmer Schedules Earnings Call for Thursday, August 4, 2022
July 14, 2022
From PerkinElmer, Inc.
Via Business Wire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap